Factors influencing ER subtype-mediated cell proliferation and apoptosis

N.M. Evers

Research output: Thesisinternal PhD, WUAcademic

Abstract

 

The aim of the current thesis is to elucidate the role of estrogen receptor (ER)αand ERβin cell proliferation and apoptosis induced by estrogenic compounds. Special attention is paid to the importance of the receptor preference of the estrogenic compounds, the cellular ERα/ERβratio, the role of coregulators, and ER-mediated induction of protein expression. In chapter 1 estrogenic compounds and their interaction with estrogen receptors are described and the two different estrogen receptors, ERαand ERβ, are introduced. It is described how estrogenic compounds eventually exert biological effects through coregulator recruitment upon ER binding, transcription initiation, and

protein expression.

Chapter 2 describes under which conditions T47D-ERβbreast cancer cells with tetracycline-dependent ERβexpression and constant ERαexpression best mimic ERα/ERβratios in breast and other estrogen-sensitive tissues in vivo in rat as well as in human. At protein and mRNA level, ERαand ERβlevels and ratios are determined in T47D-ERβcells exposed to a range of tetracycline concentrations and in rat and human breast, prostate, and uterus or endometrium. The ERα/ERβratio in rat mammary gland and in human breast tissue can be mimicked by exposing the T47D-ERβcells to >150 ng/ml tetracycline, but the ERα/ERβratio of other estrogen-sensitive rat and human tissues can also be mimicked. The ERα/ERβratios in MCF-7 and native T47D cells are high due to a lack of ERβexpression

and therefore do not reflect ratios in rat and human tissues. It is demonstrated how these different tissues might vary in their proliferative response towards 17β-estradiol (E2) by exposing T47D-ERβcells to E2 under defined tetracycline concentrations.

In chapter 3 the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by estrogenic compounds is investigated. To this end, selective ERαand ERβagonists are characterized for intrinsic relative potency reflected by EC50 and maximal efficacy towards ERαand ERβin ER-selective reporter gene assays, and subsequently tested for stimulation of cell proliferation in T47D-ERβcells with variable ERα/ERβratio and for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the Microarray Assay for Real-time Coregulator – Nuclear receptor Interaction (MARCoNI) with 154 unique nuclear receptor coregulator peptides derived from 66 different coregulators. Results obtained reveal an important influence of the ERα/ERβratio and receptor selectivity of the compounds on stimulation of cell proliferation. ERαagonists activate cell proliferation whereas ERβseems to suppress ERα-mediated cell proliferation. The responses in the MARCoNI assay reveal that the modulation of the interaction of ERαor ERβwith coregulators by a specific agonist are very similar indicating only a limited number of differences upon ERαor ERβactivation by a specific ligand. Differences in the modulation of the interaction of the ERs with coregulators between the different agonists are more substantial and can be used to classify the different agonists by hierarchical clustering. The results obtained corroborate that the ultimate effect of the model compounds on proliferation of estrogen-responsive cells depends on the intrinsic relative potency of the agonist towards ERαand ERβand the cellular ERα/ERβratio whereas differences in the modulation of the interaction of the different ERs with coregulators for a given ligand might also contribute to the compound-specific pharmacology. Based on ligand-dependent differences in the modulation of the interaction of the ERs with coregulators, the MARCoNI assay is able to classify the different ERαand ERβagonists discriminating between different agonists for the same receptor, a characteristic not defined by the ER-selective reporter gene or proliferation assays. It is concluded that differences in the modulation of the interaction of ERαand ERβwith coregulators contribute to the ligand-dependent responses but do not fully explain the differences in pharmacology between ER-mediated responses by the different estrogenic compounds.

To investigate if this is also the case for ER antagonists, chapter 4 handles the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by the ER antagonistic compounds 4-hydroxytamoxifen (4OHT) and fulvestrant. Comparison of these results to ligand-dependent interaction of ERαand

ERβwith coregulators expressed in modulation index (MI) profiles for the ER agonist E2 elucidates whether differences in the (ant)agonist-dependent interaction of ERαand ERβwith coregulators contribute to the differences in (ant)agonist responses. To this end, the selected ER antagonistic compounds are first characterized for intrinsic relative potency reflected by IC50 and maximal efficacy towards ERαand ERβusing ER-selective U2OS reporter gene assays, and subsequently tested for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the MARCoNI assay. Results obtained with the U2OS reporter gene assays indicate a preference of 4OHT to bind ERβand find fulvestrant to be less ER-specific. The responses in the MARCoNI assay reveal that ERα-

and ERβ-mediated interaction with coregulators expressed in MI profiles are similar for 4OHT and fulvestrant and generally opposite to the MI profile of the ER agonist E2. Hierarchical clustering with Euclidian distance as the cluster distance metric, based on the MI profiles, is able to clearly discriminate the two compounds with ER antagonistic

properties from the ER agonist E2. Taken together the data reveal that modulation of the interaction of ERs with coregulators discriminates ER agonists from antagonists but does not discriminate between the preferential ERβantagonistic compound 4OHT and the less specific ER antagonist fulvestrant. It is concluded that differences in modulation of the interaction of ERαand ERβwith coregulators contribute to the differences in ligand-dependent responses induced by ER agonists and ER antagonists, but the importance of the subtle differences in modulation of the interaction of ERs with coregulators between the ER antagonistic compounds 4OHT and fulvestrant for the ultimate biological effect remains to be established.

To further investigate whether 4OHT, the active metabolite of the breast cancer drug tamoxifen, exerts ERα/ERβratio-dependent effects on cell proliferation and apoptosis, in chapter 5 the results of a quantitative proteomics study are described. This is of importance given that the ERα/ERβratio usually increases in tumorous tissue compared to normal tissue due to decreased ERβexpression. ERα/ERβratio-dependent effects of 4OHT on cell proliferation and apoptosis of the T47D-ERβhuman breast cancer cell line with tetracycline-dependent ERβexpression are detected. In the cells expressing only ERαdecreased cell proliferation and increased apoptosis is induced by 4OHT, which is opposite to the effects detected in cells expressing ERαand ERβ, where increased cell

proliferation and decreased apoptosis upon 4OHT exposure is found. Post-translational modifications like acetylation, methylation, and phosphorylation of several ribosomal and mitochondrial protein groups are induced by 4OHT, mostly in T47D-ERβcells with both ERαand ERβexpressed. Altogether the results suggest that effects of 4OHT on major biological functions like cell proliferation and apoptosis in the T47D-ERβcells are affected by the ERα/ERβratio. 4OHT may have differential cellular effects, being more effective in reducing cell proliferation and increasing apoptosis if ERαdominates and ERβexpression levels are low since 4OHT then antagonizes ERα.

Chapter 6 presents a discussion on the implications of the mechanisms of action of several estrogenic compounds discussed in this thesis. Altogether the results of the present thesis have elucidated the action of different estrogenic compounds, their interaction with the two ER subtypes, and the subsequent recruitment or rejection of coregulators, as well as the resulting effects on cell proliferation and apoptosis, and these results emphasize the importance of the ERα/ERβratio for the ultimate effects of estrogenic compounds on cell proliferation and apoptosis.

LanguageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • Wageningen University
Supervisors/Advisors
  • Groten, John, Promotor
  • Rietjens, Ivonne, Promotor
  • Ederveen, A.G.H., Co-promotor, External person
Award date13 Jun 2014
Place of PublicationWageningen
Publisher
Print ISBNs9789461739469
Publication statusPublished - 2014

Fingerprint

Estrogen Receptors
Estrogens
Cell Proliferation
Apoptosis
Ligands
Cytoplasmic and Nuclear Receptors
Tetracycline
Reporter Genes
Breast
Ants
Cluster Analysis
Pharmacology
Breast Neoplasms
Proteins
Ribosomal Proteins
Mitochondrial Proteins
Tamoxifen
Human Mammary Glands
Post Translational Protein Processing
Acetylation

Keywords

  • oestrogens
  • oestrogen receptors
  • oestrogenic properties
  • tissue proliferation
  • apoptosis

Cite this

Evers, N. M. (2014). Factors influencing ER subtype-mediated cell proliferation and apoptosis. Wageningen: Wageningen University.
Evers, N.M.. / Factors influencing ER subtype-mediated cell proliferation and apoptosis. Wageningen : Wageningen University, 2014. 243 p.
@phdthesis{ebab07148eba41ebbdcf383873014de0,
title = "Factors influencing ER subtype-mediated cell proliferation and apoptosis",
abstract = "  The aim of the current thesis is to elucidate the role of estrogen receptor (ER)αand ERβin cell proliferation and apoptosis induced by estrogenic compounds. Special attention is paid to the importance of the receptor preference of the estrogenic compounds, the cellular ERα/ERβratio, the role of coregulators, and ER-mediated induction of protein expression. In chapter 1 estrogenic compounds and their interaction with estrogen receptors are described and the two different estrogen receptors, ERαand ERβ, are introduced. It is described how estrogenic compounds eventually exert biological effects through coregulator recruitment upon ER binding, transcription initiation, and protein expression. Chapter 2 describes under which conditions T47D-ERβbreast cancer cells with tetracycline-dependent ERβexpression and constant ERαexpression best mimic ERα/ERβratios in breast and other estrogen-sensitive tissues in vivo in rat as well as in human. At protein and mRNA level, ERαand ERβlevels and ratios are determined in T47D-ERβcells exposed to a range of tetracycline concentrations and in rat and human breast, prostate, and uterus or endometrium. The ERα/ERβratio in rat mammary gland and in human breast tissue can be mimicked by exposing the T47D-ERβcells to >150 ng/ml tetracycline, but the ERα/ERβratio of other estrogen-sensitive rat and human tissues can also be mimicked. The ERα/ERβratios in MCF-7 and native T47D cells are high due to a lack of ERβexpression and therefore do not reflect ratios in rat and human tissues. It is demonstrated how these different tissues might vary in their proliferative response towards 17β-estradiol (E2) by exposing T47D-ERβcells to E2 under defined tetracycline concentrations. In chapter 3 the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by estrogenic compounds is investigated. To this end, selective ERαand ERβagonists are characterized for intrinsic relative potency reflected by EC50 and maximal efficacy towards ERαand ERβin ER-selective reporter gene assays, and subsequently tested for stimulation of cell proliferation in T47D-ERβcells with variable ERα/ERβratio and for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the Microarray Assay for Real-time Coregulator – Nuclear receptor Interaction (MARCoNI) with 154 unique nuclear receptor coregulator peptides derived from 66 different coregulators. Results obtained reveal an important influence of the ERα/ERβratio and receptor selectivity of the compounds on stimulation of cell proliferation. ERαagonists activate cell proliferation whereas ERβseems to suppress ERα-mediated cell proliferation. The responses in the MARCoNI assay reveal that the modulation of the interaction of ERαor ERβwith coregulators by a specific agonist are very similar indicating only a limited number of differences upon ERαor ERβactivation by a specific ligand. Differences in the modulation of the interaction of the ERs with coregulators between the different agonists are more substantial and can be used to classify the different agonists by hierarchical clustering. The results obtained corroborate that the ultimate effect of the model compounds on proliferation of estrogen-responsive cells depends on the intrinsic relative potency of the agonist towards ERαand ERβand the cellular ERα/ERβratio whereas differences in the modulation of the interaction of the different ERs with coregulators for a given ligand might also contribute to the compound-specific pharmacology. Based on ligand-dependent differences in the modulation of the interaction of the ERs with coregulators, the MARCoNI assay is able to classify the different ERαand ERβagonists discriminating between different agonists for the same receptor, a characteristic not defined by the ER-selective reporter gene or proliferation assays. It is concluded that differences in the modulation of the interaction of ERαand ERβwith coregulators contribute to the ligand-dependent responses but do not fully explain the differences in pharmacology between ER-mediated responses by the different estrogenic compounds. To investigate if this is also the case for ER antagonists, chapter 4 handles the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by the ER antagonistic compounds 4-hydroxytamoxifen (4OHT) and fulvestrant. Comparison of these results to ligand-dependent interaction of ERαand ERβwith coregulators expressed in modulation index (MI) profiles for the ER agonist E2 elucidates whether differences in the (ant)agonist-dependent interaction of ERαand ERβwith coregulators contribute to the differences in (ant)agonist responses. To this end, the selected ER antagonistic compounds are first characterized for intrinsic relative potency reflected by IC50 and maximal efficacy towards ERαand ERβusing ER-selective U2OS reporter gene assays, and subsequently tested for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the MARCoNI assay. Results obtained with the U2OS reporter gene assays indicate a preference of 4OHT to bind ERβand find fulvestrant to be less ER-specific. The responses in the MARCoNI assay reveal that ERα- and ERβ-mediated interaction with coregulators expressed in MI profiles are similar for 4OHT and fulvestrant and generally opposite to the MI profile of the ER agonist E2. Hierarchical clustering with Euclidian distance as the cluster distance metric, based on the MI profiles, is able to clearly discriminate the two compounds with ER antagonistic properties from the ER agonist E2. Taken together the data reveal that modulation of the interaction of ERs with coregulators discriminates ER agonists from antagonists but does not discriminate between the preferential ERβantagonistic compound 4OHT and the less specific ER antagonist fulvestrant. It is concluded that differences in modulation of the interaction of ERαand ERβwith coregulators contribute to the differences in ligand-dependent responses induced by ER agonists and ER antagonists, but the importance of the subtle differences in modulation of the interaction of ERs with coregulators between the ER antagonistic compounds 4OHT and fulvestrant for the ultimate biological effect remains to be established. To further investigate whether 4OHT, the active metabolite of the breast cancer drug tamoxifen, exerts ERα/ERβratio-dependent effects on cell proliferation and apoptosis, in chapter 5 the results of a quantitative proteomics study are described. This is of importance given that the ERα/ERβratio usually increases in tumorous tissue compared to normal tissue due to decreased ERβexpression. ERα/ERβratio-dependent effects of 4OHT on cell proliferation and apoptosis of the T47D-ERβhuman breast cancer cell line with tetracycline-dependent ERβexpression are detected. In the cells expressing only ERαdecreased cell proliferation and increased apoptosis is induced by 4OHT, which is opposite to the effects detected in cells expressing ERαand ERβ, where increased cell proliferation and decreased apoptosis upon 4OHT exposure is found. Post-translational modifications like acetylation, methylation, and phosphorylation of several ribosomal and mitochondrial protein groups are induced by 4OHT, mostly in T47D-ERβcells with both ERαand ERβexpressed. Altogether the results suggest that effects of 4OHT on major biological functions like cell proliferation and apoptosis in the T47D-ERβcells are affected by the ERα/ERβratio. 4OHT may have differential cellular effects, being more effective in reducing cell proliferation and increasing apoptosis if ERαdominates and ERβexpression levels are low since 4OHT then antagonizes ERα. Chapter 6 presents a discussion on the implications of the mechanisms of action of several estrogenic compounds discussed in this thesis. Altogether the results of the present thesis have elucidated the action of different estrogenic compounds, their interaction with the two ER subtypes, and the subsequent recruitment or rejection of coregulators, as well as the resulting effects on cell proliferation and apoptosis, and these results emphasize the importance of the ERα/ERβratio for the ultimate effects of estrogenic compounds on cell proliferation and apoptosis.",
keywords = "oestrogenen, oestrogeenreceptoren, oestrogene eigenschappen, weefselproliferatie, apoptose, oestrogens, oestrogen receptors, oestrogenic properties, tissue proliferation, apoptosis",
author = "N.M. Evers",
note = "WU thesis 5778",
year = "2014",
language = "English",
isbn = "9789461739469",
publisher = "Wageningen University",
school = "Wageningen University",

}

Evers, NM 2014, 'Factors influencing ER subtype-mediated cell proliferation and apoptosis', Doctor of Philosophy, Wageningen University, Wageningen.

Factors influencing ER subtype-mediated cell proliferation and apoptosis. / Evers, N.M.

Wageningen : Wageningen University, 2014. 243 p.

Research output: Thesisinternal PhD, WUAcademic

TY - THES

T1 - Factors influencing ER subtype-mediated cell proliferation and apoptosis

AU - Evers, N.M.

N1 - WU thesis 5778

PY - 2014

Y1 - 2014

N2 -   The aim of the current thesis is to elucidate the role of estrogen receptor (ER)αand ERβin cell proliferation and apoptosis induced by estrogenic compounds. Special attention is paid to the importance of the receptor preference of the estrogenic compounds, the cellular ERα/ERβratio, the role of coregulators, and ER-mediated induction of protein expression. In chapter 1 estrogenic compounds and their interaction with estrogen receptors are described and the two different estrogen receptors, ERαand ERβ, are introduced. It is described how estrogenic compounds eventually exert biological effects through coregulator recruitment upon ER binding, transcription initiation, and protein expression. Chapter 2 describes under which conditions T47D-ERβbreast cancer cells with tetracycline-dependent ERβexpression and constant ERαexpression best mimic ERα/ERβratios in breast and other estrogen-sensitive tissues in vivo in rat as well as in human. At protein and mRNA level, ERαand ERβlevels and ratios are determined in T47D-ERβcells exposed to a range of tetracycline concentrations and in rat and human breast, prostate, and uterus or endometrium. The ERα/ERβratio in rat mammary gland and in human breast tissue can be mimicked by exposing the T47D-ERβcells to >150 ng/ml tetracycline, but the ERα/ERβratio of other estrogen-sensitive rat and human tissues can also be mimicked. The ERα/ERβratios in MCF-7 and native T47D cells are high due to a lack of ERβexpression and therefore do not reflect ratios in rat and human tissues. It is demonstrated how these different tissues might vary in their proliferative response towards 17β-estradiol (E2) by exposing T47D-ERβcells to E2 under defined tetracycline concentrations. In chapter 3 the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by estrogenic compounds is investigated. To this end, selective ERαand ERβagonists are characterized for intrinsic relative potency reflected by EC50 and maximal efficacy towards ERαand ERβin ER-selective reporter gene assays, and subsequently tested for stimulation of cell proliferation in T47D-ERβcells with variable ERα/ERβratio and for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the Microarray Assay for Real-time Coregulator – Nuclear receptor Interaction (MARCoNI) with 154 unique nuclear receptor coregulator peptides derived from 66 different coregulators. Results obtained reveal an important influence of the ERα/ERβratio and receptor selectivity of the compounds on stimulation of cell proliferation. ERαagonists activate cell proliferation whereas ERβseems to suppress ERα-mediated cell proliferation. The responses in the MARCoNI assay reveal that the modulation of the interaction of ERαor ERβwith coregulators by a specific agonist are very similar indicating only a limited number of differences upon ERαor ERβactivation by a specific ligand. Differences in the modulation of the interaction of the ERs with coregulators between the different agonists are more substantial and can be used to classify the different agonists by hierarchical clustering. The results obtained corroborate that the ultimate effect of the model compounds on proliferation of estrogen-responsive cells depends on the intrinsic relative potency of the agonist towards ERαand ERβand the cellular ERα/ERβratio whereas differences in the modulation of the interaction of the different ERs with coregulators for a given ligand might also contribute to the compound-specific pharmacology. Based on ligand-dependent differences in the modulation of the interaction of the ERs with coregulators, the MARCoNI assay is able to classify the different ERαand ERβagonists discriminating between different agonists for the same receptor, a characteristic not defined by the ER-selective reporter gene or proliferation assays. It is concluded that differences in the modulation of the interaction of ERαand ERβwith coregulators contribute to the ligand-dependent responses but do not fully explain the differences in pharmacology between ER-mediated responses by the different estrogenic compounds. To investigate if this is also the case for ER antagonists, chapter 4 handles the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by the ER antagonistic compounds 4-hydroxytamoxifen (4OHT) and fulvestrant. Comparison of these results to ligand-dependent interaction of ERαand ERβwith coregulators expressed in modulation index (MI) profiles for the ER agonist E2 elucidates whether differences in the (ant)agonist-dependent interaction of ERαand ERβwith coregulators contribute to the differences in (ant)agonist responses. To this end, the selected ER antagonistic compounds are first characterized for intrinsic relative potency reflected by IC50 and maximal efficacy towards ERαand ERβusing ER-selective U2OS reporter gene assays, and subsequently tested for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the MARCoNI assay. Results obtained with the U2OS reporter gene assays indicate a preference of 4OHT to bind ERβand find fulvestrant to be less ER-specific. The responses in the MARCoNI assay reveal that ERα- and ERβ-mediated interaction with coregulators expressed in MI profiles are similar for 4OHT and fulvestrant and generally opposite to the MI profile of the ER agonist E2. Hierarchical clustering with Euclidian distance as the cluster distance metric, based on the MI profiles, is able to clearly discriminate the two compounds with ER antagonistic properties from the ER agonist E2. Taken together the data reveal that modulation of the interaction of ERs with coregulators discriminates ER agonists from antagonists but does not discriminate between the preferential ERβantagonistic compound 4OHT and the less specific ER antagonist fulvestrant. It is concluded that differences in modulation of the interaction of ERαand ERβwith coregulators contribute to the differences in ligand-dependent responses induced by ER agonists and ER antagonists, but the importance of the subtle differences in modulation of the interaction of ERs with coregulators between the ER antagonistic compounds 4OHT and fulvestrant for the ultimate biological effect remains to be established. To further investigate whether 4OHT, the active metabolite of the breast cancer drug tamoxifen, exerts ERα/ERβratio-dependent effects on cell proliferation and apoptosis, in chapter 5 the results of a quantitative proteomics study are described. This is of importance given that the ERα/ERβratio usually increases in tumorous tissue compared to normal tissue due to decreased ERβexpression. ERα/ERβratio-dependent effects of 4OHT on cell proliferation and apoptosis of the T47D-ERβhuman breast cancer cell line with tetracycline-dependent ERβexpression are detected. In the cells expressing only ERαdecreased cell proliferation and increased apoptosis is induced by 4OHT, which is opposite to the effects detected in cells expressing ERαand ERβ, where increased cell proliferation and decreased apoptosis upon 4OHT exposure is found. Post-translational modifications like acetylation, methylation, and phosphorylation of several ribosomal and mitochondrial protein groups are induced by 4OHT, mostly in T47D-ERβcells with both ERαand ERβexpressed. Altogether the results suggest that effects of 4OHT on major biological functions like cell proliferation and apoptosis in the T47D-ERβcells are affected by the ERα/ERβratio. 4OHT may have differential cellular effects, being more effective in reducing cell proliferation and increasing apoptosis if ERαdominates and ERβexpression levels are low since 4OHT then antagonizes ERα. Chapter 6 presents a discussion on the implications of the mechanisms of action of several estrogenic compounds discussed in this thesis. Altogether the results of the present thesis have elucidated the action of different estrogenic compounds, their interaction with the two ER subtypes, and the subsequent recruitment or rejection of coregulators, as well as the resulting effects on cell proliferation and apoptosis, and these results emphasize the importance of the ERα/ERβratio for the ultimate effects of estrogenic compounds on cell proliferation and apoptosis.

AB -   The aim of the current thesis is to elucidate the role of estrogen receptor (ER)αand ERβin cell proliferation and apoptosis induced by estrogenic compounds. Special attention is paid to the importance of the receptor preference of the estrogenic compounds, the cellular ERα/ERβratio, the role of coregulators, and ER-mediated induction of protein expression. In chapter 1 estrogenic compounds and their interaction with estrogen receptors are described and the two different estrogen receptors, ERαand ERβ, are introduced. It is described how estrogenic compounds eventually exert biological effects through coregulator recruitment upon ER binding, transcription initiation, and protein expression. Chapter 2 describes under which conditions T47D-ERβbreast cancer cells with tetracycline-dependent ERβexpression and constant ERαexpression best mimic ERα/ERβratios in breast and other estrogen-sensitive tissues in vivo in rat as well as in human. At protein and mRNA level, ERαand ERβlevels and ratios are determined in T47D-ERβcells exposed to a range of tetracycline concentrations and in rat and human breast, prostate, and uterus or endometrium. The ERα/ERβratio in rat mammary gland and in human breast tissue can be mimicked by exposing the T47D-ERβcells to >150 ng/ml tetracycline, but the ERα/ERβratio of other estrogen-sensitive rat and human tissues can also be mimicked. The ERα/ERβratios in MCF-7 and native T47D cells are high due to a lack of ERβexpression and therefore do not reflect ratios in rat and human tissues. It is demonstrated how these different tissues might vary in their proliferative response towards 17β-estradiol (E2) by exposing T47D-ERβcells to E2 under defined tetracycline concentrations. In chapter 3 the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by estrogenic compounds is investigated. To this end, selective ERαand ERβagonists are characterized for intrinsic relative potency reflected by EC50 and maximal efficacy towards ERαand ERβin ER-selective reporter gene assays, and subsequently tested for stimulation of cell proliferation in T47D-ERβcells with variable ERα/ERβratio and for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the Microarray Assay for Real-time Coregulator – Nuclear receptor Interaction (MARCoNI) with 154 unique nuclear receptor coregulator peptides derived from 66 different coregulators. Results obtained reveal an important influence of the ERα/ERβratio and receptor selectivity of the compounds on stimulation of cell proliferation. ERαagonists activate cell proliferation whereas ERβseems to suppress ERα-mediated cell proliferation. The responses in the MARCoNI assay reveal that the modulation of the interaction of ERαor ERβwith coregulators by a specific agonist are very similar indicating only a limited number of differences upon ERαor ERβactivation by a specific ligand. Differences in the modulation of the interaction of the ERs with coregulators between the different agonists are more substantial and can be used to classify the different agonists by hierarchical clustering. The results obtained corroborate that the ultimate effect of the model compounds on proliferation of estrogen-responsive cells depends on the intrinsic relative potency of the agonist towards ERαand ERβand the cellular ERα/ERβratio whereas differences in the modulation of the interaction of the different ERs with coregulators for a given ligand might also contribute to the compound-specific pharmacology. Based on ligand-dependent differences in the modulation of the interaction of the ERs with coregulators, the MARCoNI assay is able to classify the different ERαand ERβagonists discriminating between different agonists for the same receptor, a characteristic not defined by the ER-selective reporter gene or proliferation assays. It is concluded that differences in the modulation of the interaction of ERαand ERβwith coregulators contribute to the ligand-dependent responses but do not fully explain the differences in pharmacology between ER-mediated responses by the different estrogenic compounds. To investigate if this is also the case for ER antagonists, chapter 4 handles the modulation of the interaction of ERαand ERβwith coregulators in the ligand-dependent responses induced by the ER antagonistic compounds 4-hydroxytamoxifen (4OHT) and fulvestrant. Comparison of these results to ligand-dependent interaction of ERαand ERβwith coregulators expressed in modulation index (MI) profiles for the ER agonist E2 elucidates whether differences in the (ant)agonist-dependent interaction of ERαand ERβwith coregulators contribute to the differences in (ant)agonist responses. To this end, the selected ER antagonistic compounds are first characterized for intrinsic relative potency reflected by IC50 and maximal efficacy towards ERαand ERβusing ER-selective U2OS reporter gene assays, and subsequently tested for ligand-dependent modulation of the interaction of ERαand ERβwith coregulators using the MARCoNI assay. Results obtained with the U2OS reporter gene assays indicate a preference of 4OHT to bind ERβand find fulvestrant to be less ER-specific. The responses in the MARCoNI assay reveal that ERα- and ERβ-mediated interaction with coregulators expressed in MI profiles are similar for 4OHT and fulvestrant and generally opposite to the MI profile of the ER agonist E2. Hierarchical clustering with Euclidian distance as the cluster distance metric, based on the MI profiles, is able to clearly discriminate the two compounds with ER antagonistic properties from the ER agonist E2. Taken together the data reveal that modulation of the interaction of ERs with coregulators discriminates ER agonists from antagonists but does not discriminate between the preferential ERβantagonistic compound 4OHT and the less specific ER antagonist fulvestrant. It is concluded that differences in modulation of the interaction of ERαand ERβwith coregulators contribute to the differences in ligand-dependent responses induced by ER agonists and ER antagonists, but the importance of the subtle differences in modulation of the interaction of ERs with coregulators between the ER antagonistic compounds 4OHT and fulvestrant for the ultimate biological effect remains to be established. To further investigate whether 4OHT, the active metabolite of the breast cancer drug tamoxifen, exerts ERα/ERβratio-dependent effects on cell proliferation and apoptosis, in chapter 5 the results of a quantitative proteomics study are described. This is of importance given that the ERα/ERβratio usually increases in tumorous tissue compared to normal tissue due to decreased ERβexpression. ERα/ERβratio-dependent effects of 4OHT on cell proliferation and apoptosis of the T47D-ERβhuman breast cancer cell line with tetracycline-dependent ERβexpression are detected. In the cells expressing only ERαdecreased cell proliferation and increased apoptosis is induced by 4OHT, which is opposite to the effects detected in cells expressing ERαand ERβ, where increased cell proliferation and decreased apoptosis upon 4OHT exposure is found. Post-translational modifications like acetylation, methylation, and phosphorylation of several ribosomal and mitochondrial protein groups are induced by 4OHT, mostly in T47D-ERβcells with both ERαand ERβexpressed. Altogether the results suggest that effects of 4OHT on major biological functions like cell proliferation and apoptosis in the T47D-ERβcells are affected by the ERα/ERβratio. 4OHT may have differential cellular effects, being more effective in reducing cell proliferation and increasing apoptosis if ERαdominates and ERβexpression levels are low since 4OHT then antagonizes ERα. Chapter 6 presents a discussion on the implications of the mechanisms of action of several estrogenic compounds discussed in this thesis. Altogether the results of the present thesis have elucidated the action of different estrogenic compounds, their interaction with the two ER subtypes, and the subsequent recruitment or rejection of coregulators, as well as the resulting effects on cell proliferation and apoptosis, and these results emphasize the importance of the ERα/ERβratio for the ultimate effects of estrogenic compounds on cell proliferation and apoptosis.

KW - oestrogenen

KW - oestrogeenreceptoren

KW - oestrogene eigenschappen

KW - weefselproliferatie

KW - apoptose

KW - oestrogens

KW - oestrogen receptors

KW - oestrogenic properties

KW - tissue proliferation

KW - apoptosis

M3 - internal PhD, WU

SN - 9789461739469

PB - Wageningen University

CY - Wageningen

ER -

Evers NM. Factors influencing ER subtype-mediated cell proliferation and apoptosis. Wageningen: Wageningen University, 2014. 243 p.